CAVITY FORMATION IN THE RABBIT MODEL OF TUBERCULOSIS by Luna, Brian M
 
 











A dissertation submitted to Johns Hopkins University in conformity with the 














© 2014 Brian M Luna 




Tuberculosis is one of the leading causes of morbidity and mortality among 
infectious diseases. The development of cavitary lesions is a major concern; it is 
believed that cavitary lesions contribute to tuberculosis disease transmission and 
antibiotic resistance. The progression of cavitary lesions can also be a sign of 
treatment failure. Despite the health significance of cavitary tuberculosis, there is 
currently no test or assay to assess which patients would be most likely to 
develop cavitary disease. Tests capable of detecting early treatment failure could 
be useful in clinical trial settings and save a considerable amount of money for 
failed drugs, as clinical trials are expensive due to long-term treatment and follow 
up monitoring required for tuberculosis. In this work, a non-invasive imaging tool 
is presented that is capable of predicting which rabbits will continue to progress 
to develop cavitary disease. Next a RNA sequencing study was performed to 
measure the global transcriptome response of the host at the cavitary lesion. 
One of the genes identified as being upregulated in the cavitary tissue was  
mmp-1. We hypothesized that MMP-1 was involved in cavitary lesion 
development and tested our hypothesis by treating M. tb infected rabbits with a 
small molecule, RO32-3555 (Trocade), which inhibits MMP-1 activity.   
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Chapter 1: Introduction 
 
Although tuberculosis is one of the oldest diseases known to affect man, it 
remains one of the major causes of morbidity and mortality worldwide [1]. 
Tuberculosis typically presents as a pulmonary infection and the disease is 
spread by aerosol transmission of the bacterial pathogen Mycobacterium 
tuberculosis. One third of the global population is estimated to be infected with 
latent tuberculosis. Individuals affected by latent tuberculosis do not have clinical 
symptoms and are not infectious. However, individuals with latent disease are at 
risk of developing active disease. Southeast Asia and Africa were responsible for 
29% and 27% of total tuberculosis cases in 2012 (Figure 1-1). Mortality is higher 
among men, but TB remains one of the top 10 killers globally for women. [2]  
 
A standard six month, four drug antibiotic treatment regimen is recommended for 
drug susceptible cases; however, complications such as drug resistance or 
cavitary diseases can extend the treatment duration for up to two years [3]. There 
are three major factors that prolong the duration of treatment. One major 
challenge in shortening the treatment regimen is the successful killing of bacterial 
persisters, a subpopulation of bacteria that are able to survive in the presence of 
antibiotics. The persister population is thought to represent about 1% of the total 
bacterial population and requires prolonged treatment to ensure the sterilization 
of all bacteria [4, 5]. A deficiency of good biomarkers or sampling options is 
another challenge for rapidly assessing the successfulness of a treatment 
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regimen, since sites of infection and disease burden are difficult to identify 
without robust biomarkers [6]. Lastly, tissue remodeling of the lung during the 
course of disease progression can lead to pathology that can have negative 
implications for drug distribution and penetration within lesions [7, 8]. While these 
three challenges are relevant to the study and treatment of tuberculosis, these 
are not unique to tuberculosis. This thesis will discuss advances in non-invasive 
imaging techniques that attempt to elucidate the pathogenesis of cavitary 
tuberculosis.   
 
1.1 The rabbit model of cavitary tuberculosis 
 
Mice, guinea pigs, rabbits, and non-human primates have been the traditional 
animal models for studying tuberculosis (Table 1-1: Animal models of 
cavitation). Mice do not develop true granulomas which are one of the 
pathologic hallmarks of tuberculosis classically observed in humans. Granulomas 
are defined as densely organized cellular structures that are formed as a host 
immune response in an attempt to create a microenvironment that walls off the 
pathogen from the rest of the body (Figure 1-2). Guinea pigs can develop 
granulomas, and the pathology is very similar to what is observed in humans; 
however, guinea pigs do not develop cavities. Rabbits and non-human primates 
both develop granulomas and cavities that are similar in pathology as to what is 
seen in humans, making these animals the better models for cavitary 
tuberculosis research (Figure 1-3) [9]. The rabbit model has historically been the 
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most important model for the study of cavitary tuberculosis, and much of what is 
currently known about cavitary disease was studied in the rabbit model [9-13]. 
Rabbits provide the most accessible small animal model that is capable of 
modeling cavitary disease. However, the rabbit model does have its limitations, 
which are due to relatively few molecular and genetic tools available. After the 
rabbit genome became available though, the number of bioinformatic tools have 
expanded and the availability of the genome has now made global gene 
expression and systems biology studies possible through the use of microarrays 
or RNA-sequencing platforms [14-17].  
 
The rate of cavity development, the number of cavities, and the frequency at 
which cavities develop is partially dependent of the species and strain of 
Mycobacterium that is used for infection. It is also possible to presenstitize 
rabbits, a process that makes rabbits hypersensitive to mycobacterial antigen, 
increasing the rate and frequency with which cavitary lesions develop [11, 13]. 
The work presented in this thesis is based on a presensitized rabbit model 
(Figure 1-4).  
 
One theory regarding the progression of cavitary tuberculosis is that the 
development of cavitary lesions is driven by the host immune response [11, 18, 
19]. Presensitization of rabbits also offers support that these lesions are formed 
as a consequence of a host immune response. Cleavage and remodeling of the 
lung extracellular matrix, a necessity for cavity lesion formation, requires special 
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proteases of the matrix metalloproteinase (MMP) class. These proteases are 
released during the inflammatory response and remodel the lung extracellular 
matrix. It is not believed that Mycobacterium tuberculosis has the capabilities to 
degrade the lung extracellular matrix and therefore the development of the 
cavitary lesions are driven by the host immune response (Figure 1-5) [20-24].   
 
1.2 PET/CT imaging 
 
X-rays were first discovered by Wilhelm Röntgen in 1895 and these discoveries 
would later lead to a Nobel prize in 1901. It did not take long for the X-rays to be 
applied to the health sciences and the field of radiology began in its infancy in the 
early 20th century.  
 
Computed tomography (CT) imaging is a form of x-ray imaging that allows for the 
acquisition of multiple X-ray slices and then the subsequent reconstruction of the 
image stack to generate a 3D data set with information in the x, y, and z planes. 
Briefly, the CT scanner consists of an X-ray source located opposite a detector 
inside of a doughnut shaped housing apparatus. The subject to be scanned is 
placed inside the scanner and is situated between the X-ray source and the 
detector. The X-ray source and detector rotate around the subject and acquire 
multiple scans. The data set of 2D X-ray scans is then reconstructed into voxels, 
a unit of value that  consists of volume and 3D spatial information (Figure 1-6). 
These voxels are then compiled to make the 3D reconstructed images.  
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The data acquired from a CT scan is quantifiable. Each voxel represents a 
numerical value that is representative of X-ray attenuation. The numeric values 
are defined in the Hounsfield unit (HU) scale.  The formula for determining the 
Hounsfield unit is determined by Equation 1. The value “0” on the Hounsfield 
scale is defined as the attenuation of water and the value of “-1000” is defined as 
the attenuation of air.  Measurements made by the CT scanner are important for 
providing structural information. It should be noted that a CT scan requires many 
X-rays for the reconstruction of a 3D image, and therefore a patient receiving a 
CT scan receives more radiation as compared to a standard X-ray. 
 
Equation (1) 𝐇𝐔 = [𝛍(𝐱) − 𝛍(𝐰𝐚𝐭𝐞𝐫)] ÷ 𝛍(𝐰𝐚𝐭𝐞𝐫) 
 
A positron emission tomography (PET) scan is a functional radioimaging 
technique. PET scans require the use of a radioactive tracer. The tracer provides 
both the signal and also the target specificity. The housing apparatus for a PET 
scanner is similar to a CT scanner, expect a PET scanner does not have a 
radiation source. The sole radiation source for a PET scan is the administered 
PET tracer.  
 
The decay of the radiotracer produces a positron. Positrons and electrons 
annihilate and produce two high energy gamma rays that travel in opposite 
directions at an angle of approximately 180 degrees relative to each other 
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(Figure 1-7). The instruments are able to take advantage of each annihilation 
event producing two decay products that travel in nearly opposite directions by 
creating cutoffs of what can be considered a true signal as opposed to random 
background noise. These correction factors increase the sensitivity and 
specificity of the signal detected and also aid in determining the spatial origin of 
where an annihilation event occurs. The gamma rays are not able to be directly 
measured and therefore, the quantification of the gamma rays requires the aid of 
scintillation crystals and photomultiplier tubes. The scintillation crystals convert 
the high energy gamma rays into photons that are passed along to the 
photomultiplier tube. The photomultiplier tube converts the photons into an 
electrical current and the electrical current can then be measured and quantified.  
 
1.3 Infectious disease imaging 
 
CT provides a tool to visualize structural changes in anatomy during disease 
progression. However, it should be noted that CT is not capable of visualizing 
individual pathogens, nor is it able to distinguish all stages of infection. 
Appreciable structural changes at the initial stage of infection would most likely 
be below the limit of detection. Similarly, late stage changes in the resolving of 
the disease would also be difficult to distinguish as it is likely that structural 
changes would linger beyond the clearance of the pathogen. The utility of CT can 
therefore be summarized as being the most useful during active disease when 
structural changes are occurring and are visible. CT would also be useful in 
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monitoring the decrease in disease related pathology as an indicator of the 
transition from the active stage to the resolving stage of the disease, but CT 
would not be an effective end point measure of disease.  
 
Molecular imaging techniques and tools for infectious disease imaging, such as 
PET imaging, have traditionally been largely focused on measuring the process 
of inflammation. Inflammation is a general process that includes changes such as 
the increased vascular permeability and the recruitment of immune cells. 
Examples of these imaging techniques are the ex-vivo labeling of white blood 
cells and then tracking their migration, the labeling of macromolecules and 
measuring increased vascular permeability, and the labeling of circulating 
activated white blood cells in-vivo. It is important to note that these techniques do 
not directly label the pathogen, but rely on the indirect labeling of the host 
immune cells and the concentration of the probe at sites of inflammation [25].  
 
Recently, the use of  [18F]-2-fluoro-deoxy-D-glucose ([18F]-FDG) has gained 
popularity for its application to infectious disease imaging. The tracer is a 
modified glucose sugar and is taken up by the GLUT-1 transporter. The [18F]-
FDG sugar is then phosphorylated by hexokinase and the product, [18F]-FDG-6-
phosphate, is not able to undergo further metabolism by the cell and therefore is 
trapped inside the cell [26]. Clinical use of [18F]-FDG first began with the 
oncology field. It was observed that cancer cells were highly metabolically active 
and would readily uptake higher amounts of glucose. In the context of infectious 
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diseases imaging, [18F]-FDG is still labeling highly metabolically cells but the cells 
being labeled are host immune cells such as neutrophils and macrophages [27]. 
Recent advances have been made in the development of pathogen specific 
tracers. The most common approach to date has been the modification of 
antibiotics to include a radioisotope (Table 1-2) [28-30].  
 
There remains a need for improved non-invasive imaging probes and imaging 
techniques for infectious disease imaging. While the probes listed in Table 1-2 
are a significant advancement on the previous generation of probes targeting the 
inflammation process, these probes are still not capable of differentiating 
bacterial species. The potential benefits of improved non-invasive imaging would 
include the ability for rapid localization of the site of infection, diagnosis of the 
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Figures 
 
Figure 1-1: Estimated TB incidence rate for 2012 
The highest density of new TB cases were reported from Africa. India is the 
country with highest total number of new TB cases and represents approximately 
29% of all new TB cases. The United States would not be considered a TB 
endemic country. There were about 1.3 million deaths due to TB in 2012.  
  
  12 
 
Figure 1-2: TB pathogenesis 
Inhaled bacteria are first phagocytosed by alveolar macrophages. This is 
followed by the recruitment of additional host immune cells to contain the 
infection in a process called granuloma formation. In the host that is resistant to 
cavitary lesions,  the granuloma serves to isolate the encompassed bacteria in a 
microenvironment that is isolated from the rest of the host. It is possible for 
bacteria to persist and survive in this granuloma structure. In the susceptible 
host, the granuloma is unable to contain the replication of the bacteria. The 
bacteria are able to replicate to high numbers in the caseous center of the lesion. 
Eventually the structure of the lesion deteriorates and the lesion ruptures which 
allows the release of free extracellular bacteria into the airway. It is important to 
note that the pattern of lesion development should result in an increasingly dense 
structure prior to cavitation and after cavitation occurs the lesion should become 
a decreasingly dense structure.  
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Figure 1-3: Cavity lesion in rabbits and humans 
Cavitary lesions in rabbits is similar to the cavitary lesions that develop in 
humans. Tuberculosis cavity formation results in the formation of large air filled 
structures that are identifiable by gross pathology. Bacteria are able to replicate 
to high numbers in the caseous cavity space and rupture of the cavity wall into 
the airway allows for direct access of the bacilli to the airway which is an 
important step for disease transmission.  
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Figure 1-4: Rabbit cavity lesion 
CT and PET scans were taken of the same animal at pre-cavitation and post-
cavitation timepoints. A dense lesion that shows high [18F]-FDG uptake is 
observed in the top right portion of the lung. This lesion then goes on to cavitate 
within the next 7 days. After cavitation occurs, the cavity wall still shows high 
uptake of [18F]-FDG tracer. The process of presensitizing the rabbits allows for a 
more rapid development of cavitary lesion development and also development of 
lesions in a higher proportion of rabbits than what may be observed in non-
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Figure 1-5: MMP degradation of extracellular matrix 
Cavitary lesions develop as result of extracellular matrix degradation. 
Degradation of the host extracellular matrix is believed to be driven by the host 
matrix metalloproteinase enzymes as shown by the pathway on the right side. 
The left hand pathway is the classical description of cavitary formation, but the 
classic description does not detail how the extracellular matrix is cleaved. 
Necrosis is not a sufficient mechanism to degrade the extracellular matrix. 
Elkington, P. T., D'Armiento, J. M., and Friedland, J. S. (2011). Tuberculosis 
immunopathology: the neglected role of extracellular matrix destruction. Science 
Translational Medicine 3, 71ps6–71ps6. 
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Figure 1-6: CT scanner schematic 
Schematic of a CT scanner. The X-ray source is housed opposite the detector in 
a doughnut shaped setup. The subject is placed on a bed in between the the X-
ray source and detectors in a stationary position. The X-ray source and detector 
rotate around the subject acquiring multiple X-rays during the course of the 
rotation. The reconstructed stack of images is then used to create a 3D 
visualization of the subject. Matter which is of higher density will attenuate the X-
ray more compared to matter which is of a lower density. X-ray attenuation is 
represented by the Hounsfield unit (HU) scale with water and air defined as  0 
HU and -1000 HU respectively. Reprinted from  Goldman, L. W. (2007). 
Principles of CT and CT technology. J Nucl Med Technol 35, 115–28– quiz 129–
30. 









Figure 1-7: PET scanner schematic 
Schematic of a PET scanner. A positron is formed during the decay of the 
radioisotope and the resulting positron collides with an electron. This annihilation 
event is detected by scintillation crystals that convert the high energy gamma 
radiation into photons. The photons are the quantified by photomultiplier tubes. 
The source of the radionuclide with vary depending on the imaging tracer utilized. 
Image reprinted from Verel, I., Visser, G. W. M., and van Dongen, G. A. (2005). 
The promise of immuno-PET in radioimmunotherapy. Journal of Nuclear 
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Table 1-1: Animal models of cavitation 
The development of cavitary lesions is one of the hallmark characteristics of 
human tuberculosis. Rabbits are the smallest laboratory animal that develop 
cavitary disease. The frequency and rate of cavitation in rabbits can be increased 
by presensitizing rabbits to mycobacterium prior to infection.  Mice do not 
develop granulomas or cavitary lesions. The table was reprinted from Helke, K. 
L., Mankowski, J. L., and Manabe, Y. C. (2006). Animal models of cavitation in 
pulmonary tuberculosis. Tuberculosis 86, 337–348. 
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Table 1-2: Bacteria specific PET probes 
Below is a table of microbial specific PET probes. The majority of the probes 
have used known antibiotics as the backbone to provide specificity for the PET 
tracers. Several of the tracers listed below provide specificity at the genus level, 





UBI 29-41 bacteria, fungus 
FIAU bacteria, herpes virus 
ciprofloxacin bacteria 
fleroxacin bacteria 
trovafloxacin bacteria  
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Rationale: Cavity tuberculosis is a risk factor for transmission and antibiotic 
treatment failure. There are no clinical tests available that test for the risk of 
cavitary lesion development. Objectives: To define a non-invasive imaging 
algorithm that is predictive of cavitary lesion development using a rabbit model of 
cavitary tuberculosis. Methods: We conducted a training study in which we 
collected and analyzed 114 PET/CT imaging data sets. We designed our 
predictive algorithms based on the data from this training data set and then 
validated our algorithms on a test data set collected from a second rabbit study 
consisting of 38 PET/CT imaging data sets. Measurements and Main Results: 
In the test data set, the PET ROI predicted cavitary disease with 100% sensitivity 
and 76% specificity and use of the CT ROI predicted cavitary disease with 83.3% 
sensitivity and 76.9% specificity. Conclusions: We were able to predict the 
development of cavitary lesions 1 week in advance. Our results show that 
restricting our analysis to regions with high [18F]-FDG uptake provided the best 
combination of sensitivity and specificity. Inclusion of additional criteria to 
improve the predictive power of the algorithm warrants further study. 
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Introduction 
 
In 2011, tuberculosis (TB) was responsible for an estimated 1.4 million deaths 
[1]. Mycobacterium tuberculosis (M. tb) is the primary etiological agent of TB in 
humans [2]. The initial infection is usually cleared or otherwise contained by the 
host immune system in a granuloma. Cavities evolve when solid caseous 
necrotic granulomas liquefy [3, 4]. Cavities are a risk factor for disease 
transmission [5-9]. The tissue destruction that results from cavitation contributes 
to the morbidity and mortality of TB [4, 10-12]. Cavitary disease is also an 
indicator of treatment failure and disease relapse [9, 13-15]. 
  
There are no clinical tests that are designed to assay the risk of cavitary lesion 
development and thus there is a need for markers to address this shortcoming 
[16-19]. Imaging markers provide an attractive option due to their benefit of 
providing a real-time, non-invasive tool. Additionally, non-invasive imaging tests 
allow for monitoring disease progression within a patient over time. 
  
We used a rabbit cavitary model of TB to develop imaging markers predictive of 
cavitary lesion development. In this study, we demonstrate that while 
inflammation, as measured by [18F]-fluorodeoxyglucose ([18F]-FDG) uptake does 
not positively correlate with cavitary disease, changes in lung density as 
measured by CT are predictive of cavitary lesion development. We believe this 
novel method can be used as a non-invasive tool to analyze the progression of 
  25 
TB disease and to identify the population most at risk for developing cavitary 
lesions. Such imaging biomarkers could shorten the time and cost of TB drug 
trials and are valuable in evaluating therapeutics which target the cavitation 
process. 
  
Materials and Methods 
 
Ethics statement 
All animal experiments were carried out in strict accordance with the 
recommendations in the “Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health” and all procedures were approved by the Johns 
Hopkins University Animal Care and Use Committee. 
  
Modified rabbit cavitary model 
Sensitization and infection of New Zealand White female rabbits were done as 
previously described [20]. Briefly, rabbits received 5 separate injections of 108 
CFUs of heat killed M. bovis Ravenel. Twenty-five days after the final injection 
the animals were given a skin test using purified protein derivative [PPD] to 
measure hypersensitivity. Positivity was defined as any measurable induration. 
Animals which did not convert their skin test were still included in this study. 
Following the skin test results, rabbits were challenged with 104 live M. 
tuberculosis H37Rv bacilli. The bacterial suspension was delivered to the right 
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lower lung lobe by bronchoscopy. Inoculum dose was determined by plating the 
inoculum on 7H11 selective plates. 
  
 [18F]-FDG PET/CT imaging 
Rabbits were anesthetized with ketamine (20 mg/kg), xylazine (5 mg/kg), and 
acepromazine (10 mg). Animals were maintained under 3 L/min O2 and 1% 
isoflurane for the duration of the imaging. Because the imaging facility is located 
in a BSL-2 facility, the infected animals were placed into a biosafety imaging 
chamber (Mediso). This chamber allowed for the filtration of gas exchange and 
for the safe transport of the animal. 2 mCi of [18F]-FDG was administered 
intravenously by the marginal ear vein. PET scans were acquired on a Philips 
Mosaic PET scanner. 45 minutes post injection, PET data was acquired by a 30 
minute static scan. CT scans were performed with a clinical 8-slice CereTom CT 
(NeuroLogica) scanner. 
  
Imaging processing, segmentation, coregistration, and ROIs 
An overview of the image processing is summarized in figure 2-1 and figure 2-
2. Fiducial markers were used to coregister PET scans to the CT scans. A group 
of 5 thin-walled PCR tubes containing 5 µCi of [18F]-FDG were used as the 
fiducial markers. Rigid image coregistration was done using AMIRA 
(Visualization Science Group). Image segmentation was done using both AMIRA 
and the ANNOTATION TOOL (NIH) software packages. Methods for image 
segmentation were followed as described by Bagci et al. [21]. Briefly, lung 
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segmentation was conducted by an adaptive region growing algorithm in which 
the user defined voxels were labeled as being “lung” or “non-lung” regions [22]. 
Explicitly labeled voxels are used to determine the status of the unlabeled voxels. 
Furthermore, manual interaction for refinement of dense pathological regions 
within the lung was also possible using the brush tools or random walk region 
segmentation algorithm [21, 23]. The segmented lung regions were then 
converted into binary masks such that non-lung regions were removed from the 
raw images. PET ROIs were defined by thresholding the top 5 percentile of [18F]-
FDG uptake. CT ROIs were defined as being between −200:200 Hounsfield HU. 
  
Statistical analyses. 
Statistical analysis was done using PRISM (GraphPad Software). For analysis 
which consisted of comparing multiple time points, statistical significance was 
determined by a repeated measures 1-way ANOVA with a Bonferroni’s multiple 
comparison test. For pairwise analysis, a 2-tailed, unpaired student T-test was 
done. P values of less than 0.05, 0.01, and 0.001 were summarized as *, **, and 
*** respectively. P values of less than 0.05 were considered non-significant. 
   
Results 
 
Rabbit model of cavitary disease training set. We used a modified version of 
the rabbit cavitary model reported by Nedeltchev et al [20] which produced 
cavitation in about 50% of animals within 5 weeks post-infection. Twelve rabbits 
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were presensitized with a series of 5 injections of 108 heat killed M. bovis bacilli 
suspended in incomplete Freund's adjuvant and infected with 104 colony forming 
units (CFUs) of M. tuberculosis H37Rv. The rabbits underwent PET/CT scans at 
the following time points: pre-infection, and on days 14, 21, 28, 35, 70, and 140 
post-infection. In total 114 image sets, comprised of 57 PET and 57 CT data 
sets, were collected and analyzed. Cavitary progressive disease was defined by 
visual assessment of a cavity structure during necropsy or observing a region 
with density value less than −900 Hounsfield units (HU) as measured by CT. 
Animals in which no cavitary disease was observed were labeled as having non-
cavitary progressive disease. 
  
PET and CT regions of interest (ROI). Raw PET and CT images were 
acquired, coregistered, and then segmented. The PET ROI was defined as a 
global threshold of the top 5 percentile of [18F]-FDG uptake, and the CT ROI was 
defined by the density range of -200:200 HU. The PET and CT ROIs were 
applied to the segmented PET and CT data sets, respectively (Figure 2-1, 
Figure 2-2A). The PET ROI can be summarized as defining a region with high 
inflammation; and the CT ROI can be summarized as defining a consolidated 
region. Both regions identify abnormalities that can be interpreted as signs of 
disease. A summary of the main types of pathology that are visualized by CT are 
summarized in Figure 2-3A. Because PET and CT images have been 
coregistered, application of the ROI is not restricted to the data set used to 
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generate the ROI. For example the spatial volume defined by the PET ROI can 
be applied to the CT image set and also the PET data set (Figure 2-2B). 
  
Uptake of [18F]-FDG was not discriminative for cavitary progressing disease 
versus non-cavitary progressing disease. It has been previously reported that 
uptake of [18F]-FDG is a marker of inflammation and disease progression both 
animal models and also human TB disease. Additionally, uptake of [18F]-FDG has 
been shown to be useful in measuring antibiotic treatment efficacy [24-26]. To 
investigate whether the uptake of [18F]-FDG can differentiate cavitary progressive 
from non-cavitary progressive disease, the standardized uptake value maximum 
(SUVmax) was measured for each animal using the PET ROI. No significant 
difference could be found in cavitary progressing animals compared to non-
cavitary progressing animals on day 14, which was seven days prior to the time 
of cavitation for 80% of the rabbits (Figure 2-4A). 
  
We then measured the total distribution of [18F]-FDG standardized uptake within 
the segmented lung field on day 14 (Figure 2-4B). There was no significant 
difference in PET signal when examining the transition time from pre-cavitation to 
cavitation. We measured no significant difference in [18F]-FDG uptake when in 
either CT ROI or PET ROI was used (Figure 2-4 C-D). 
  
Changes in lung density during disease progression. Progression of active 
TB disease in the rabbit model leads to structural changes, such as fibrosis, that 
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can be measured as an increase in lung tissue density (Figure 2-3B). Changes 
in density can be measured by CT, and it was observed that the distribution of 
lung density changes over time (Figure 2-5). A significant difference (p = 0.0038) 
was found when comparing the lung density distribution in cavitary progressive 
animals the week of cavitation versus the week prior to cavitation (Figure 2-3B). 
A significant difference was also observed when measuring the density 
distribution at the week of cavitation compared to the week prior to cavitation 
using the PET ROI (two-tailed unpaired t-test) (Figure 2-3C, Figure 2-6). The 
density distribution of cavitary progressing animals did show an increasing trend 
in the 0:100 HU domain in the CT ROI (Figure 2-3D). 
  
Defining an imaging marker of cavitation. We observed that the shifts in the 
density distribution from the PET ROI produced a peak in the −200:200 HU 
region (Figure 2-7). It was also observed that a significant increase (p = 0.0003), 
in lung density in range of −200:200 HU occurs after infection (Figure 2-8A). 
There was a significant difference (p = 0.0001) between cavitary progressing and 
non-cavitary progressing animals when measuring the percentage of lung within 
the −200:200 HU range (Figure 2-8B). 
  
To better refine the HU range that was enriched in cavitary progressing animals, 
we calculated the sum of differences between day 14 cavitary progressing 
animals (4) and non-cavitary progressing animals (7) (Figure 2-6A). Equation 1 
calculates the difference of sums for a particular cavitary progressing animal 
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defined as yj  and non-cavity progressing animals defined as xi . The difference of 
sums can then be plotted as shown in Figure 2-6A. The domain of the curve (x-
values) that corresponds to the range of y >0 represents the HU that are 
enriched in the cavitary progressive animals. Alternatively, the domain of the 
curve that corresponds to the range of y < 0 represents the HU units that are 
underrepresented in the cavitary progressive animals. The individual curves 
generated by Equation 1 can be summarized by calculating the sum of sums 
which is represented by Equation 2 (Figure 2-6B). The domain of 3.3-69.34 HU 
was identified from Figure 2-6B as being enriched in cavitary disease. We next 
checked if the area under the curve (AUC) for this domain was similarly different 
when measuring the density distribution in either the PET ROI or the CT ROI. We 
found that the density distribution was significantly different for both ROIs (p < 
0.0001) (Figure 2-9 A-B). 
  
Assessment of the predictive power of the imaging markers using the test 
set. We developed two methods for predicting cavitary lesion progression using 
the data we collected from the training set series of animals. The methods 
quantify the density distribution as measured by CT using differently defined 
ROIs. The cutoffs of AUC > 90 and AUC > 115, for the PET and CT ROIs 
respectively, were positive predictors for the development of cavitary disease. 
These criteria were designed to provide the best combination of both sensitivity 
and specificity. Scans defined as positive were the week of cavitation and the 
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week prior to cavitation. Therefore the training set consisted of 10 positive 
imaging sets, and 47 negative imaging sets (Table 2-1, Figure 2-9C). 
  
To validate the utility of these methods, these predictive criteria were applied to a 
new test set of rabbits. The test set was subjected to the same infection 
conditions as the training set group. Three out of four animals developed cavitary 
disease from the test set. The test set were imaged at pre-infection, 1, 2, 3, and 5 
weeks post-infection and consisted of 6 positive scans and 13 negative scans 
(the week 5 scan from one rabbit was not used because it represented 2 weeks 
after cavitation occurred in this animal). Use of the PET ROI predicted cavitary 
disease with 100% sensitivity and 76% specificity and use of the CT ROI 
predicted cavitary disease with 83.3% sensitivity and 76.9% specificity (Table 2-
1, Figure 2-9C). Cavitary lesions that were identified by PET/CT imaging were 
consistent with histopathology findings as well (Figure 2-10). Cavitary disease 




Tuberculosis biomarkers for monitoring disease outcome are urgently needed. 
The use of imaging biomarkers could have an immediate impact in a clinical trial 
setting in which resources are more abundant. At present, the cost of clinical 
trials for new TB vaccines and drugs is staggering because of poor biomarkers. 
Identification of robust biomarkers to monitor treatment outcome could 
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dramatically reduce both the financial cost and study duration needed to evaluate 
new therapeutics [17, 18, 27]. 
  
Also, while it is true that TB is a disease that mainly affects the poor and 
underserved populations, the use of computational radiology techniques are not 
out of reach. For example the financial costs of providing radiology services are 
cheaper in India compared to the US [28]. There are current efforts to expand 
radiology services to underserved populations for public health reasons [29]. 
Treatment and clinical care of TB could be aided by improved imaging 
capabilities. While we show that the PET ROI provides the best sensitivity, the 
CT ROI does provide respectable prediction power. This is important because 
the resources for CT imaging are more widely available than the resources for 
PET imaging. 
  
The improved sensitivity of predicting cavitary disease for the PET ROI 
compared to the CT ROI is likely due to a positive correlation between [18F]-FDG 
uptake and inflammation. Inflammation results in the release of enzymes capable 
of remodeling the extracellular matrix. The role of proteases and collagenases 
and their necessity for producing the disease pathology typically observed in TB 
has previously been reported [4, 11, 12]. 
  
It is important to note that increasing uptake of [18F]-FDG was observed during 
disease progression, consistent with recent studies [24-26, 30-32]. These studies 
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established that [18F]-FDG uptake is correlated with CFU burden. While it has 
been reported that cavities provide an environment for high bacterial burden, it is 
unknown if a high bacterial burden is a necessary prerequisite for cavitary 
formation [20, 33, 34]. It is plausible that the CFU burden prior to cavitation was 
similar between cavitary and non-cavitary groups and therefore there was a 
similar uptake of [18F]-FDG. The density region that we observed to be increased 
during the course of disease progression was also independently reported in a 
marmoset model recently published by Via et al [31]. This suggests that the 
density region that we identified in this study may have more broad application 
outside of the rabbit model. 
  
Currently our algorithms are able to predict cavitary disease up to 1 week in 
advance of cavitation. However we believe it may still be possible to improve the 
predictive power beyond 1 week by incorporating additional non-radiological tests 
that were not included in the present study. Tests such as sputum smear 
microscopy, Interferon-Gamma Release Assays (IGRAs), quantification of lung 
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Figures 
Figure 2-1: Algorithms for predicting cavitary disease.  
The algorithms outline the steps involved in both the processing and analysis of 
image data sets. The basic steps involved are to co-register PET and CT data 
sets, segment the lung region, define a ROI, apply the ROI to the CT data set, 
and to calculate the AUC to evaluate if the animal is expected to develop cavitary 
disease. A) Algorithm which applies a PET ROI to the CT data set. B) Algorithm 
which applies a CT ROI to the CT data set. 
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Figure 2-2: Image segmentation and registration.  
A) Outline of the process of image coregistration and segmentation. a) CT 
coregistered image. b) PET coregistered image. c) CT/PET coregistered image 
fusion. d) Binary mask generated from segmentation of the lung by CT. e) 
Product of image “B” x “D”. f) Product of image “A” x “D”. g) A representative 3D 
reconstruction of the PET and CT segmented image data. B) Image shows the 
visual representations of the PET ROI and CT ROI. The upper panels of 
represent the region of the lung included in the CT ROI and the bottom panels 
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Figure 2-3: Density change in cavitary progressing and non-cavitary 
progressing groups.  
PET and CT image sets were first coregistered and the lung field was defined by 
CT. A binary mask of the CT defined lung field was then multiplied against the 
PET image stack to define the lung field in the PET image stack. Subsequent 
ROIs were defined by either CT or PET as described below. A) A general 
representation of the densities associated with different disease pathologies 
observed by CT. “A” represents a cavity, “B” represents normal lung, and “C” 
represents a region of consolidation. B) Density as measured from the 
segmented, total lung reconstruction. A significant difference was observed 
between the two groups (p = 0.0038) C) Density distribution within the CT ROI. 
The cavitary progressing group showed increased density in the 0:100 HU 
domain. D) Density distribution within the PET ROI. A significant difference was 
observed between the groups (p = 0.038). 
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Figure 2-4: Change in [18F]-FDG SUVmax between cavitary progressing and 
non-cavitary progressing groups over time. 
A) There is no difference in [18F]-FDG SUVmax between cavitary-progressing 
and non-cavitary progressing disease D14. B) [18F]-FDG uptake as measured 
from the segmented, total lung image, showing no significant difference. C) PET 
uptake in the CT ROI. No significant difference was observed between groups. 
D) PET uptake in the PET ROI. No significant difference was observed. 
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Fig. 2-5: Change in total lung density over time.  
Lung regions were manually segmented prior to analysis. The graphs represent 
the change in lung density (HU units) as measured by CT. Appearance of cavity 
by CT is denoted as “Cav”. The black, filled in histogram is the pre-infection 
baseline. A peak in the 0:100 HU range can be observed in cavitary progressing 
animals. 
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Fig. 2-6: The sum of differences and sum of sums.  
The domain of the curve (x-values) that corresponds to the range of y >0 
represents the HU that are enriched in the cavitary progressive animals. 
Alternatively, the domain of the curve that corresponds to the range of y < 0 
represents the HU units that are underrepresented in the cavitary progressive 
animals. A) The sum of differences as calculated by Equation 1 for individual 
cavitary progressing animal. B) The sum of differences as calculated by Equation 
2. 
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Figure 2-7: Change in lung density in PET ROI.  
Lung regions were manually segmented and the ROIs were defined by uptake of 
[18F]-FDG tracer. The graphs represent the change in lung density (HU units) as 
measured by CT. Appearance of cavity by CT is denoted as “(Cav)”. 
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Figure 2-8: Change in the proportion of densely consolidated lung tissue.  
Total lung regions were defined by manual segmentation. Densely consolidated 
tissue was defined by the range −200:200 HU. A) The change of densely 
consolidated tissue over time. B) The change of densely consolidated tissue by 
disease state. There is a significant difference in the amount of lung 
consolidation present in cavitary progressing and non-cavitary progressing 
rabbits at day 14.  
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Figure 2-9: AUC test for predicting cavitary progression.  
The AUC corresponding to the range defined by 3.3-69.34 HU was found to be 
significant (p < 0.0001, two-tailed unpaired t-test) for A) CT ROI and B) PET ROI. 
C) ROC curves which use either PET or CT defined ROIs. All curves perform 
similarly. Each step in the curve corresponds to an increasing cutoff value of the 
AUC which would be defined as positive. As the curves progress to the right of 
the graph there is a decrease in sensitivity but an increase in specificity. 
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Figure 2-10: Rabbit cavity lesion.  
A) A cavity lesion is shown by the crosshairs in a M. tb infected rabbit. The cavity 
is identifiable as a region of low density by CT and uptake of the PET tracer is 
localized to the cavity wall. Localization of PET tracer uptake to the cavity wall is 
expected since the cavity is air filled and void of any cells capable of taking up 
the tracer. B) Confirmation of a cavity lesion by histopathology. Tissue was 
stained by H&E stain. The inset shows a 10x magnified view.  
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Table 2-1: Sensitivity and specificity of cavitary predictive radiology 
markers.  
Use of the Pet* ROI outperformed the CT* ROI. 
  
Training Set. 
10 True Positive. 
55 True negatives. 
 Test Set. 
6 True Positives. 
13 True negatives. 
 
ROI PET CT PET CT 
AUC 90 115 90 115 
Sensitivity 90 80 100 83.333 
Specificity 78.182 72.727 76.923 76.923 
  
 Table 2-2: Concept box 
Terms Definitions 
Standardized Uptake Value 
(SUV) 
Unit of normalized uptake of PET tracer. 
SUV = (pixel dose (mCi/CC) * body weight (kg))/ injected 
dose (mCi) 
Region of Interest (ROI) An arbitrary region of interest defined by the analyst 
Hounsfield Units (HU) Scale of density measured by CT. Air = -1000 HU, water = 0 
HU, and bone = 1000 HU 
Coregistration The process of spatially transforming image “a” to align 
with image “b” 
Segmentation Dividing an image into defined parts 
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Chapter 3: RNA-seq of host expression profile in a rabbit 




Rationale: Cavitary disease is thought to form as the result of an unfavorable 
host immune response. The rabbit is capable of modeling cavitary tuberculosis 
disease, however the lack of commercial tools for studying the genetic and 
molecular host factors have made progress slow in studying the rabbit host 
response. Objectives: Microarrays have been the standard for assessing global 
expression changes, however these tools are currently unavailable for rabbits. 
Here we present a study in which we perform a RNA-seq analysis of the rabbit 
host response to cavitary disease. Methods: 3 Female New Zealand White 
rabbits were challenged with live virulent M. tb H37Rv strain and cavitary lesions 
were allowed to develop. 3 female New Zealand White rabbits were included in 
the study as uninfected controls. From the infected rabbit group, RNA was 
extracted from the cavity wall and from uninvolved tissue from the contralateral 
lung. RNA was also isolated from 3 non-infected control animals. Total RNA was 
extracted by the TRIZOL method and sequenced using the AB SOLiD deep 
sequencer. Measurements and Main Results: A total of 8737 transcripts were 
mapped and 3380 transcripts were unmapped. For pathway analysis using the 
Ingenuity Pathway Analysis software, we used a 3-fold (log2) cutoff and identified 
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194 differentially expressed genes. The uninvolved tissue clustered better with 
the naive tissue and the cavity wall was distinctly different from uninvolved and 
naive samples. mmp-1 was among the most upregulated genes in the cavity wall 
compared to naive or uninvolved tissue. Cell recruitment, wound healing, and 
microbial response pathways were all significantly upregulated.  Conclusions: 
Because CFUs were culturable from the uninvolved lung, the expression 
changes observed were not simply due to the presence or absence of bacteria. 
The data is consistent with the hypothesis that cavitary lesions are driven by the 




Tuberculosis is one of the major causes of morbidity and mortality due to a single 
bacterial pathogen [1].  Development of cavitary lesions have negative 
implications for both drug treatment efficacy and disease transmission [2]. It is 
believed that the breakdown of the lung extracellular matrix is necessary for the 
development of cavitary lesions and that matrix remodeling is a host driven 
process [3-5]. Granulomas and cavitary lesions are pathological hallmarks of 
human tuberculosis disease. BALB/c and C57BL/6 mice, the most common mice 
strains used historically for tuberculosis research, do not develop granulomas 
and cavitary lesions. Rabbits and non-human primates do develop granulomas 
and cavitary lesions, additionally the disease pathology developed by these 
animal models looks similar to tuberculosis pathology in humans [6-11].   
 
Despite the abundance of genetic and molecular tools available for the mouse 
which make the mouse an attractive model system, the mouse does not faithfully 
recapitulate cavitary disease and is therefore not the appropriate system to study 
cavitary lesion development. Rabbits are the most accessible laboratory animal 
that reliably develops cavitary disease, and the majority of research concerning 
cavitary disease has been done in the rabbit model [11].  
 
One of the limitations regarding the rabbit model is the relative lack of genetic 
and molecular tools compared to those available for other model organisms. 
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However the availability of the sequenced rabbit genome allows for the use of 
PCR based assays such as RNA sequencing. RNA sequencing provides a 
platform for whole genome expression analysis with unbiased results [12, 13].  
 
Prior to RNA sequencing, microarrays have been the primary platform for global 
gene expression studies. The basic principle behind microarrays is that labeled 
samples are washed over a slide that contains unlabeled probes specific to 
targets of interest. The relative abundance is determined by the signal intensity 
from binding of labeled samples and mapping of the probe provides information 
about the identity of the hybridized sample. While microarrays have proven to be 
extremely valuable research tools, there remains one major technical hurdle 
inherent to microarray assays. Microarrays can only provide information for 
targets in which probes have been printed. This means that there needs to be 
some knowledge of the potential targets before the microarray is designed [14]. 
The result is that microarrays are of limited utility for the identification of novel 
events such as novel splice variants or unannotated transcripts.   
 
One important benefit of RNA sequencing as compared to microarrays is that 
that RNA sequencing does not require prior knowledge of the expected 
transcripts and is therefore not constrained by the need to design probes to the 
prospective targets of interest [13]. RNA sequencing provides a more robust and 
unbiased platform for measuring whole genome expression compared to 
microarray assays.  
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In this study we use RNA sequencing as a way of interrogating the host response 
to cavitary disease. We then did a pathway analysis to determine which 
biologically relevant pathways were differentially expressed using a commercially 
available software, Ingenuity Pathway Analysis (IPA). Next we confirmed our 
pathway analysis by using the Gene Set Enrichment Analysis (GSEA) software 
package [15, 16]. Lastly, we used a third analysis package, the Tuxedo Suite, for 
identifying unannotated transcripts [17]. 
 
Materials and Methods 
 
Ethics Statement 
All animal experiments were carried out in strict accordance with the 
recommendations in the “Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health” and all procedures were approved by the Johns 
Hopkins University Animal Care and Use Committee. 
 
Rabbit Sensitization and infection 
Rabbits were presensitized and infected as described previously [18]. Briefly, 
rabbits were administered a series of 5 subcutaneous injections of a 1:1 
suspension of Freund's incomplete adjuvant mixed with 1 x 108 heat killed bacilli. 
The injections were spread out over 2.5 weeks and the rabbits were 
subsequently allowed to rest for 2.5 weeks. Rabbits were administered a PPD 
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test to confirm sensitization. Prior to infection rabbits were anaesthetized with a 
combination of ketamine (17-35 mg/kg), xylazine (5-10 mg/kg), and 
acepromazine (0.75 mg/kg). Rabbits were infected by depositing a bacterial 
suspension containing 104 colony forming units (CFU) of live, virulent M. tb 
H37Rv strain in the right lower lobe of the lung by bronchoscopy. The CFU of the 
infectious suspension was determined by serial dilution and plating on 7H11 agar 
plates.   
 
Necropsy  
Rabbits were anaesthetized with ketamine (17-35 mg/kg), xylazine (5-10 mg/kg), 
and acepromazine (0.75 mg/kg) and then euthanized with 3 ml of Euthasol 
Euthanasia Solution (Virbac Animal Health, Fort Worth, Texas). Following 
euthanasia, rabbits were necropsied and the lungs were harvested. Lung tissue 
from cavitary animals were separated by gross pathology into cavity wall, 
granulomatous, and uninvolved groups. Tissue for RNA extractions were stored 
immediately in RNAlater (Ambion).  
 
RNA extraction 
Lung samples were stored in RNAlater (Ambion) per manufacturer’s protocol. 
Lung tissue was homogenized in TRIZOL (Invitrogen) using a bead beater and 2 
mm glass beads. RNA was extracted by following the TRIZOL protocol. RNA was 
further purified using the RNeasy kit (Qiagen) following the manufacturer's 
protocol. RNA was eluted and cleaned, prior to Turbo DNAse treatment 
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(Ambion). Final RNA concentration was measured by Nanodrop (Nanodrop 
2000C ThermoScientific, DE, USA), and adjusted to 0.5 µg/µl. The RNA is then 
converted to cDNA by the Agilent Superscript cDNA synthesis kit (Agilent, CA) 
according to the manufacturer’s protocol. RNA integrity was determined with the 
Agilent 2100 Bioanalyzer (Agilent Technologies) and mRNA was enriched for 
using the RIBOMinus kit according to the manufacturer’s protocol (Life 




The library preparation of rRNA depleted RNA was done using the Applied 
Biosystems SOLiD Total RNA-Seq kit (Applied Biosystems) according to the 
manufacturer's protocol. RNA was fragmented and purified using the Invitrogen 
RiboMinus Concentration Module (Life Technologies). The size distribution was 
determined by the Bioanalyzer using the RNA 6000 Pico Chip Kit (Agilent 
Technologies). RNA yield was quantified using the Qubit Fluorometer (Life 
Technologies). Library amplification was done using the Applied Biosystems 
SOLiD Total RNA-Seq kit and samples were barcoded with unique 3’ primer. The 
quality of the library was assessed using the DNA1000 chip and the Agilent 
Bioanalyzer. Libraries were quantified by qPCR and equimolar concentrations 
were amplified by emulsion PCR and 50 bp paired end sequencing was done on 
the AB 5500xl SOLiD deep sequencer (Applied Biosystems).  
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Sequencing reads were aligned to the Oryctolagus cuniculus genome (ensembl, 
release-70, <ftp://ftp.ensembl.org/pub/release-70/fasta/oryctolagus_cuniculus/>) 
using the Bioscope 1.3 Whole Transcriptome Analysis Pipeline software package 
(Applied Biosystems). HTSeq-count v0.5.3 was used to calculate the number of 
reads per transcript.  The DESeq v1.4.1 R package (bioconductor.org) was used 
for calculating differential expression between groups. Transcripts with adjusted 
p-values < 0.05 were considered differentially expressed.  
 
Tuxedo Suite  
Determination of differential expression was done using the Tuxedo protocol as 
described in Trapnell et al 2012 [17]. Briefly, raw transcript reads are aligned to a 
reference genome using TopHat. The aligned transcripts from TopHat are then 
passed to Cufflinks in which transcripts are assembled. Because it is possible 
that not all isoforms of a gene may be expressed in a cell at a given time, it is 
necessary to create a definition of a gene which includes all isoforms. The 
Cuffmerge tool is used to merge transcript assemblies from multiple transcript 
assembly files to create a comprehensive view of the gene. Lastly Cuffdiff is used 
to calculate differential expression and CummeRbund was used for interacting 
with the data.  
 
Ingenuity Pathway Analysis (IPA) 
Because IPA does not officially supports the rabbit model, rabbit gene names 
were converted to orthologous mouse gene names. Fragment reads per kilobase 
64 
pairs (FPKM) and adjusted p-values were calculated using the DESeq package. 
Pathway analysis was restricted to genes that met the following conditions: 3x 
(log2) differential expression, lung organ restricted, non-cancer cell line, and non-
neurological cell. Pathway analysis was done using the built in Core Analysis and 
Functional Gene Set Enrichment tools.  
 
Gene Set Enrichment Analysis (GSEA) 
To confirm the functional gene set enrichments identified by through the IPA 
platform, a secondary analysis was done using the freely available Gene Set 
Enrichment Analysis (GSEA) software (Broad Institute) [15, 16]. The same 
starting data table with orthologous mouse gene names and the respective p-
values were used for the analysis. Curated functional gene sets from the 




Differentially expressed genes 
RNA was isolated from 3 distinct tissue types: cavity wall, uninvolved, and naive 
(Figure 3-1). There were a total of 12,117 mapped transcripts. 8737 of these 
transcripts were successfully converted to a mouse orthologue gene IDs for use 
in pathway analysis through Ingenuity Pathway Analysis (IPA) or Gene Set 
Enrichment Analysis (GSEA) tools. The remaining 3380 transcripts were 
hypothetical or did not share a orthologue with the mouse genome. 903 putative 
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unnamed genes were differentially expressed in the cavity wall and uninvolved 
lung tissue. The 903 genes further breaks down into 196 and 807 genes that 
were upregulated in the cavity wall and uninvolved lung tissue respectively. The 
naive and uninvolved samples clustered closer together when comparing the 
global expression changes, and the cavitary sample was distinctively different 
(Figure 3-2). 
 
Analysis was done using Fragments Per Kilobase of exon per Million fragments 
mapped (FPKM). The FPKM value provides a normalized value which allows for 
the relative comparison of genes with different transcript length. The MMP class 
of enzymes was well represented among the top 20 overexpressed genes in the 
cavity wall, consisting of mmp-1, mmp-13, and mmp-3 (Table 3-1). While there 
were many genes that were upregulated in the cavitary tissue compared to the 
uninvolved tissue, there was only 1 gene that were uniquely expressed only in 
the cavitary tissue at high abundance, q2lda4. Other genes that were uniquely 
expressed in the cavity wall were present at FPKM reads of less than 50 and 
were considered low abundance transcripts.   
 
Differentially expressed pathways 
Use of the IPA platform yielded functional gene sets involving the inflammatory 
response, infectious disease response, respiratory disease, and connective 
tissue disorders that were all found to be upregulated in the cavity wall (Table 3-
2). Pathways involved with extracellular matrix remodeling were also found to be 
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significantly differentially expressed in the cavity wall tissue (Table 3-2 and 
Table 3-3).   
 
For validation of the IPA results, we conducted a second pathway analysis using 
the GSEA software tool. The GSEA tool is an open ended pathway analysis tool 
in which the user supplies a functional gene list with the corresponding gene 
identifiers. For our analysis we used the KEGG and Reactome functional gene 
sets. Upregulation of the inflammatory response was also identified using the 
GSEA software tool, suggesting that IPA identified pathways were in fact 
differentially expressed (Figure 3-3). Additional pathways such as the cell death 
and cell proliferation pathways were also identified using the GSEA tool, however 
due to the different definitions of functional gene sets across the KEGG, 
Reactome, and IPA libraries, it was not always possible to find identical 
functional gene set definitions across the different libraries. Lastly, the libraries 
require different gene identifier annotations which creates another layer of 
complexity when trying to directly compare gene sets across platforms. While we 
feel confident that there is a similarity  among the pathway analysis using the 
KEGG, Reactome, and IPA libraries, quantitation of the overlap proved to be 
difficult. For these reasons we will focus only on the data generated from the IPA 
analysis.   
 
The process of inflammation is known to be involved with tuberculosis disease 
[19, 20]. Inflammation is a host immune response that describes processes such 
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as the release of chemokines and cytokines, increased vascular permeability, 
recruitment of immune cells, and immune cell proliferation. It has been shown 
that naive macrophages are recruited to the site of mycobacterium infection to 
attempt to control the spread of bacteria [21, 22]. Differential expression of 104 
genes comprising the cellular growth and proliferation pathway were differentially 
expressed and the pathway was found to be enriched in the cavitary tissue 
compared to the uninvolved tissue (p=1.41E-16). Cellular proliferation is most 
likely due to the activation of the immune system and proliferation of immune 
cells. Cellular proliferation would suggest that the disease state is in an 
inflammatory stage.  
 
Also supporting the process of a local inflammatory response at the site of 
cavitation are upregulation of cellular migration pathways. There were 47 genes 
differentially expressed in the in the immune cell trafficking pathway and the 
pathway was found to be upregulated in the cavitary wall (p= 3.54E-14). There 
were 44, 34, and 26 genes differentially expressed in the pathways involving the 
activation of leukocytes, monocytes, and T-cells respectively and the pathways 
were enriched in the cavitary wall tissue (p={5.25E-15, 1.86E-12, 2.30E-10}). The 
enrichment of cell proliferation, cell migration, and cell activation pathways in the 
cavity wall tissue suggests that cavitary lesions are associated with the 
recruitment of activated immune cells. 
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Tissue destruction and cell death are observed in cavitary lesions. Cell death can 
occur through apoptosis which is a programmed cell death pathway, or through 
necrosis which is a non-programmed cell death pathway. Our data indicates that 
both processes are enriched for in the cavitary lesion. 70 genes are differentially 
expressed in the apoptosis pathway (p= 4.48E-9) and 55 genes in the necrosis 
pathway (p = 9.79E-9).  
 
IFN-gamma signaling was predicted to be a significant transcriptional regulator in 
the cavitary lesion. A putative signaling cascade modeling IFN-gamma signaling 
network was created (Figure 3-4). Enrichment of the IFN-gamma network is 
associated with a proinflammatory immune state. NFkB activation is of interest 
because there remain conflicting reports about the involvement of NFkB in the 
immune response to tuberculosis [23, 24]. NFkB is known to influence T cell 
division and also promote the production of the proinflammatory cytokine IL-6.  
Cavitary lesion development may be a specific situation in which NFkB is 
upregulated and helps drive a proinflammatory response.  
 
Lastly, it is possible to make a de novo pathway map that shows the most likely 
signaling relationships based on the expression data set. In this study we 
developed a model that described a relationship that incorporates the 
relationship between TNF-alpha, a major factor in the inflammation process, and 
with extracellular matrix remodeling proteases such as MMP-1 (Figure 3-5). Both 
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of these factors have been reported in the literature to be upregulated at both the 




The rabbit build used for the analysis of the sequencing data (GenBank 
Assembly ID GCA_000003625.1, release build 70 ) has been sequenced to a 7x 
coverage depth and the overall depth of coverage and annotation quality are not 
at the current standard as model organisms such as the mouse or rat genomes. 
It was estimated that about 80% of the genome was properly anchored to a 
chromosome, and the remaining sequences were annotated as a virtual 
chromosome.  While the genome build quality was sufficient for the RNA seq 
analysis, there are currently some limitations. It would be possible to re-run the 
sequencing analysis using an updated reference sequence to improve the 
annotation at a later date.  
 
It was also surprising that the expression data from uninvolved lung tissue 
harvested from M. tb infected animals clustered better with lung tissue from 
naive, non-infected rabbits. Bacteria was culturable from the uninvolved lung 
tissue and it is therefore not possible to attribute the similarity between the 
uninvolved and naive tissue as being because both tissue lacked bacilli. We 
cannot rule out that there is a threshold of bacterial burden that needs to be 
reached in order to observe expression changes that differ from naive lung. 
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Another possible explanation for why the global gene expression of uninvolved 
tissue clusters well with the naive tissue could be due to our infection model. 
Rabbits are infected by bronchoscope and a bolus infectious dose is deposited in 
right lower lung lobe. It could be possible that the infection is so intense and 
focused in a discrete area that there is immune cell depletion in other areas of 
the lung as intensive immune cell trafficking is targeted to the site of infection. 
 
Despite the limitations of some the current genome build there is still a 
considerable amount of data that was generated and is interpretable. A number 
of previously identified immune related pathways were identified in our study and 
identification of these pathways serve as a good control for our data set and 
analysis. Upregulation of the inflammatory response is typical of tuberculosis and 
that finding would be expected to be represented at the gene expression level. 
 
More research is needed to investigate what the major mechanism of cell death 
is during cavitary disease. It is not possible from our data set to extrapolate which 
pathway is the predominant death pathway. Identification of which cell death 
pathway is predominant would allow for further research investigating if 
modulating the cell death pathway towards either necrotic or apoptotic pathways 
would be beneficial for the host in the context of cavitary lesion development.  
 
Traditional explanations about the process of cavitary lesion development have 
focused on necrotic and proinflammatory processes. However, neither of these 
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explanations specifically address the process for breaking down the extracellular 
matrix. Involvement of the MMP class of enzymes in the destruction of the 
extracellular matrix provides a testable hypothesis for the specific mediator of 
extracellular matrix degradation. It is therefore encouraging that our expression 
data reflects both the proinflammatory response and additionally the specific 
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Figure 3-1: RNA tissue sampling 
Lungs were harvested from presensitized New Zealand White rabbits after the 
cavities were confirmed by CT scan. RNA was isolated from specific regions as 
determined by gross pathology. RNA was additionally isolated from a naive, non-
infected rabbit. Rabbits were infected using by bronchoscope and the infection is 






Figure 3-2: Tuxedo global clustering 
A heatmap representing the global gene expression changes among the samples 
collected. The gene expression pattern was distinctively different compared to 
the uninvolved and cavity wall tissue. The uninvolved and naive tissue samples 
displayed a higher amount of clustering than originally anticipated. Because 
CFUs were culturable from the uninvolved tissue from M. tb infected animals it 
the major difference in gene expression clustering between cavity wall and 





Figure 3-3: Reactome immune response gene set 
In addition to the IPA functional gene set analysis, the freely available GSEA 
software was used as well. A list of functional gene sets was downloaded from 
the reactome database and a functional gene set enrichment analysis was done. 
Similar to the IPA results, the immune response functional set was also found to 
be upregulated in the cavity wall sample. Similar identification of upregulated 
pathways using different functional gene set definitions and different analysis 
software provides support that the identified functional pathways are truly 







Figure 3-4: IPA IFN-gamma network 
IFN gamma is known to be important for the a successful host response to 
Mycobacterium tuberculosis. This network describes the putative cavitary 






Figure 3-5: IPA cavity signaling 
A novel network summary that best describes the gene expression changes 
measured in the cavitary wall compared to the uninvolved lung tissue. MMP-1 
and and TNF alpha play a central role in the map and it has previously been 
suggested that both of these host factors are important for the development of 
cavitary lesions. This putative map describes the combined involvement of both 




Table 3-1: Top 10 most upregulated genes present in cavitary tissue.  
A list of the most upregulated genes present in the cavity wall tissue compared to 
the uninvolved tissue. mmp1, mmp13, mmp3, and cthrc1 are involved with 
maintenance and remodeling of the extracellular matrix in part due to their 
functional ability of cleaving collagen.    
Gene Name log2 fold change adj. p 
mmp-1 11 9.77E-55 
bozyq7 (cxcl13) 10 5.87E-24 
b6a7p9 9 4.49E-11 
q8hyv6 9 4.27E-23 
vtnc 8 1.37E-08 
mmp-13 8 1.49E-24 
ubd 8 1.87E-26 
mmp-3 8 3.32E-36 
cthrc1 7 1.87E-26 




Table 3-2: IPA core analysis functional gene sets 
Significantly differentially regulated gene sets in the cavitary compared to 
uninvolved samples. Of the functional gene sets identified, the majority were 
related to inflammation and the immune response. The table was generated 
using the IPA software package. The inflammatory pathway and connective 
tissue disorders pathways were significantly upregulated. The connective tissue 
disorders gene set includes the upregulation of proteases such as the MMP class 

















 p-value # of Molecules 
Diseases and Disorders   
Inflammatory Response 5.25E-15   - 2.49E-04       79 
 
Connective Tissue Disorders 3.76E-11   - 1.44E-05       27 
 
Inflammatory Disease 3.76E-11   - 1.01E-10       26 
 
Skeletal and Muscular Disorders 3.76E-11   - 1.01E-10      26 
Immunological Disease 1.01E-10   - 2.44E-04 24 
   
Molecular and Cellular Functions   
Cell-To-Cell Signaling and 
Interaction 
6.21E-17 - 2.49E-04  82 
Cellular Growth and Proliferation 1.41E-16 - 2.70E-04         109 
Cellular Function and Maintenance 1.29E-14 - 2.51E-04        69 
Cellular Movement 3.54E-14 - 2.44E-04        68 
Cellular Development 1.30E-12 - 2.70E-04         94 
   
Physiological System 
Development and Function 
  
Hematological System 
Development and Function 
7.82E-18   - 2.70E-04       103 
Tissue Morphology 7.82E-18   - 1.92E-04      73 
Immune Cell Trafficking 5.25E-15   - 2.49E-04       68 
Humoral Immune Response 5.81E-12   - 2.38E-04      29 
Cell-mediated Immune Response 6.33E-11   - 2.51E-04       38 
83 
Table 3-3: IPA core analysis molecules 
Molecules that were upregulated in the cavity sample. MMP1, MMP13, and 
MMP3 were among the most upregulated molecules identified by IPA. The MMP 
family of enzymes have been shown to have functional roles in remodeling the 
extracellular matrix.  
 p-value 
Top Canonical Pathways  
Hepatic Fibrosis 2.36E-10 
Role of HyperCytokinemia in the Pathogenesis of Influenza 1.17E-09 
Atherosclerosis Signaling 1.39E-09 
Role of Osteoblasts, Osteoclasts and Chondrocytes in 
Rheumatoid Arthritis 
2.8E-08 
Pathogenesis of Multiple Sclerosis 1E-07 
  













Chapter 4: Small molecule inhibition of MMP-1 alters 




Rationale: The development of cavitary lesions is an important risk factor to 
disease transmission and antibiotic treatment failure in tuberculosis. Inhibition of 
cavitary lesion development could be an important adjunctive therapy for 
treatment of tuberculosis, as none of the current drugs used for the treatment of 
tuberculosis have any specific activity aimed at the inhibition of cavity formation. 
Objective: Breakdown of the extracellular matrix requires the activity of special 
enzymes of the matrix metalloprotease (MMP) class. MMP-1 is upregulated in 
tuberculosis patients and this enzyme is thought to be important for remodelling 
of the extracellular matrix. RO32-3555 is a small molecule inhibitor of MMP-1 and 
it is hypothesized that inhibition of MMP-1 will inhibit the development of cavitary 
lesions. Methods: New Zealand White rabbits were presensitized and infected 
with M. tb H37Rv by bronchoscopy. Rabbits were divided into three groups and 
treated with either RO32-3555, INH, or vehicle alone daily. Disease progression 
was monitored by weekly breath hold CT scans acquired at 20 cm of water 
pressure. At necropsy lungs were fixed with formalin at a set pressure of 20 cm 
and the fixed lungs were analyzed by histopathology. Main Results: In the first 
infection group, the RO32-3555 treated animals showed reduced lung pathology 
by CT up until 2 weeks postinfection (week 2, p<0.001). The RO32-3555 treated 
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animals showed the highest lung consolidation at week 5 (p<0.001). In the 
second study, the RO32-3555 group showed the greatest amount of lung 
consolidation at week 2 post infection (p<0.001). Rabbits developed cavities in all 
treatment groups but the size and volume of cavities was lowest in the RO32-
3555 group. Conclusions: Preliminary data suggest that use of the inhibition of 





Tuberculosis (TB) was responsible for 1.3 millions deaths in 2012 [1]. The 
disease is caused by the pathogen Mycobacterium tuberculosis (M. tb). During 
the early stages of infection M. tb is phagocytosed by host alveolar macrophages 
and additional lymphocytes are recruited to the site of infection to form a 
granuloma. Cellular recruitment and lung matrix remodeling during granuloma 
development serve the purpose of creating an isolated microenvironment for 
containment of the bacilli [2-6].  
 
Studies have shown that tumor necrosis factor alpha (TNF-α) is important for 
proper granuloma formation and that inhibition of TNF-αresults in a granuloma 
disorganization [7-9]. Other studies have shown that the addition of TNF-
αinhibitors to the standard tuberculosis antibiotic regimen results in faster 
clearance of bacteria from the host [10]. Liquefaction of the granuloma lesion is 
suggested to precede the formation of a cavitary lesion [11].  
 
Reduced lung pathology and cavitation have been observed in 
immunosuppressed HIV-TB coinfected individuals [12-15]. It is predicted that the 
host matrix metalloproteinase (MMP) class of enzymes are responsible for 
remodeling of the lung extracellular matrix during M. tb infection [16-18]. Taken 
together, these data suggest that tissue destruction is driven by a host mediated 
response and not a direct action by the bacteria.  
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Bacteria are able to replicate to high numbers in the cavity and a combination of 
the high bacterial numbers and cavity structure contribute to presence of cavitary 
lesions as being a risk factor for transmission and antibiotic treatment failure [19-
21]. Therefore, inhibiting cavity lesion formation may reduce the relative 
infectiousness of an individual and reduce the rate of antibiotic treatment failure.  
 
The standard treatment regimen for tuberculosis consists of isoniazid, rifampicin, 
ethambutol, and pyrazinamide. None of the previously mentioned drugs possess 
any anti-MMP activity and none of the drugs directly inhibits tissue destruction 
processes. Inhibition of lung matrix remodelling would be an attractive adjunctive 
therapy that could be introduced for TB treatment [17, 18]. Destruction of the 
extracellular matrix is not a quickly reversible process and changes such as 
cavitation may persist [22, 23]. Therefore it would seem that prevention of tissue 
remodeling would be the preferential.  
 
The main mechanical extracellular matrix components of the lung are collagen 
(type 1 and IV) and elastin [24]. The MMPs that are capable of cleaving collagen 
are MMPs 1, 8, and 13. MMP 9 is a gelatinase but it also possesses collagenase 
activity [25]. MMP-1 has previously been reported to be elevated in tuberculosis 
patients [13, 16]. Additionally in a humanized mouse model expressing the 
human mmp-1 gene, mice infected with M. tb developed disease pathology more 
closely resembling human disease pathology [17].  
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In this study we hypothesised that the inhibition of MMP-1 would reduce the lung 
pathology that is typically observed in tuberculosis. Rabbits, not mice, express 
MMP-1 in the lung and therefore we tested our hypothesis by treating M. 
tuberculosis infected rabbits with RO32-3555 (Trocade) and graded lung 
pathology by non-invasive computed tomography (CT) imaging and by 
histopathology [17, 26]. RO32-3555 is a pharmacologically relevant small 
molecule inhibitor of MMP-1 which has been shown to be safe in humans [26]. 
Inhibition of tissue destructive processes would be an attractive adjunctive 





All animal experiments were carried out in strict accordance with the 
recommendations in the “Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health” and all procedures were approved by the Johns 
Hopkins University Animal Care and Use Committee. 
 
Set pressure CT imaging 
Rabbits were anesthetized with ketamine (20 mg/kg), xylazine (5 mg/kg), and 
acepromazine (10 mg). Animals were maintained under 3 L/min O2 and 1% 
isoflurane for the duration of the imaging. Because the imaging facility is located 
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in a BSL-2 facility, the infected animals were placed into a biosafety imaging 
chamber. This chamber allowed for the filtration of gas exchange and for the safe 
transport of the animal.  
 
Rabbits were intubated with a 3.0 mm cuffed endotracheal tube. The 
endotracheal tube was connected to a Y-port in which one connection was 
exposed to the ambient environment of the container and was controlled by an 
on/off valve. The other Y-port was connected to the gas supply. Pressure was 
regulated by sealing the port connected to the ambient environment of the inside 
of the container and thus creating a closed system with the gas supply. The 
pressure of the gas supply was set by adjusting the height of a water trap to the 
desired depth of either 20 cm of water. 
 
Image processing, segmentation, ROIs, and longitudinal coregistration 
Images were preprocessed using FIJI (NIH). Image segmentation was done 
using the AMIRA (Visualization Science Group) software package. Pathological 
regions of interest (ROI) were manually segmented from individual slices. The 
esophagus and main bronchi were segmented and removed from analysis of the 
lung region.  
 
Rigid coregistration of longitudinal data sets was done using the coregistration 




Sensitization and infection 
Adult female New Zealand White rabbits weighing 3.5-4.0 kg were used for this 
study. M. bovis was grown in 7H9 broth culture, cell density was adjusted to a 
concentration of 1 x 109 CFU/ml, and heat killed at 72 C for 3 hours. The heat 
killed suspension was mixed 1:1 with Freund’s incomplete adjuvant and 0.2 mls 
of this suspension was administered for the sensitization injections. Rabbits were 
given a series of 5 sensitization injections over the course of 2.5 weeks and then 
the rabbits were rested for an additional 2.5 weeks.  
 
Rabbits were anaesthetized with a combination of ketamine, xylazine, and 
acepromazine. Anaesthetized rabbits were infected with live, virulent 
Mycobacterium tuberculosis H37Rv strain using a bronchoscope. 0.4 mL of a 
bacterial suspension was deposited in the lung and the total CFU was 
determined by plating the inoculum on 7H10 plates. For the first infection study 
animals were infected with bacteria that were previously frozen at -80C and 
thawed the day of infection. For the second infection study rabbits were 
challenged with actively growing, log-phase cultures. 
 
Necropsy 
Rabbits were anaesthetized with a combination of ketamine, xylazine, and 
acepromazine and then euthanized with Euthasol euthanasia solution. The lungs 
were fixed with 10% neutral buffered formalin (NBF) by hanging a bag containing 
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10% NBF at 20 cm above the surface of the safety cabinet in which the necropsy 
was performed. The thoracic ribs were removed to expose the heart and lungs. 
While leaving the organs inside the animal, the lungs were flushed through the 
trachea 4x with 30 mls of Ringer’s solution. A line connected to a reservoir of 
10% NBF was placed in the trachea. The trachea was tied off with sutures to 
create a closed system with the bag of 10% NBF and the lungs. The lungs were 
insufflated with 10% NBF for 30 minutes and the heart/lung block were removed 
from the rabbit and placed in a jar containing 500 mls of 10% NBF. After 24 
hours the heart/lung block was trimmed and the trimmed lungs were returned to 
fresh 10% NBF.  
 
Histology 
Formalin fixed paraffin embedded tissues were sectioned and stained by 
Histoserv (Germantown, MD). Serial sections were stained with H&E, acid fast, 
Masson’s trichrome, and picrosirius red stains. Pathology assessment was 
performed by a trained veterinary pathologist.  
 
Oral dosing of rabbits 
RO32-3555 (Roche, USA) was resuspended in Pediasure (Abbott Nutrition, 
Ohio) at a concentration of 100 mg/ml. Rabbits were treated orally with 100 
mg/kg of RO32-3555 on weekdays. Vehicle control rabbits were given Pediasure 
alone and INH treated rabbits were given 25 mg/kg or INH dissolved in water. 
Drug or vehicle solutions were administered with a veterinary feeding needle at 
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the back of the tongue to ensure the animals swallowed the dose. Treatment was 





Rabbits were infected with 4.01 (log10) CFU of M. tb H37Rv from a frozen stock. 
Following infection rabbits were treated with RO32-3555, INH, or vehicle daily on 
weekdays (Figure 4-1). Rabbits in the INH treatment group began losing weight 
rapidly after treatment. Treatment was halted for 1 week and the animals were 
allowed to regain their weight. Following the weight gain, rabbits in the INH 
treatment group resumed their treatment but INH was dissolved in water instead 
of Pediasure. The rabbits did not have any further weight loss complications after 
the change of the INH vehicle solution.  
 
Lung consolidation was monitored by weekly breath hold CT imaging. RO32-
3555 treated rabbits showed reduced lung consolidation at early timepoints up 
until 2 weeks post infection (p<0.001 at week 2), but the effect of the drug was 
lost at later timepoints. At weeks 4 and 5 postinfection, the RO32-3555 treated 
rabbits showed the highest lung consolidation relative to the other treatment 
groups (p<0.001 for week 4 and 5). The INH treated rabbits consistently showed 
the least amount of lung consolidation (Figure 4-2).  
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Animals were necropsied after 5 weeks post infection and lungs were harvested 
and formalin fixed for histopathology. It was also observed that the RO32-3555 
treated animals showed the presence of vasculitis as determined by 
histopathology (Figure 4-3). The presence of vasculitis was also observed in the 
vehicle control group but not in the INH treated group. While the frequency of 
occurrence was not different in RO32-3555 versus the vehicle group, however 
the severity of vasculitis appeared to be worse. Vasculitis had not been 
previously associated as a side effect of the drug.  
 
Group 2 
Rabbits were infected with with 4.24 (log10) log-phase growth M. tb H37Rv. 
Following infection rabbits were treated with RO32-3555, INH, or vehicle daily on 
weekdays (Figure 4-4). Due to the complications that arose from the INH being 
resuspended in Pediasure as a vehicle, water was used vehicle solution for INH. 
No weight loss issues were observed.  
 
Lung consolidation was monitored weekly as previously described. Imaging was 
done at preinfection and at day 7 and day 14 postinfection (Figure 4-5). Animals 
were necropsied after 2 weeks post infection and lungs were harvested and 
formalin fixed for histopathology.  
 
The relative amount of lung consolidation represented by the 3 treatment groups 
did not follow the same trend that was observed in the first group. At week 1 
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there was no significant difference between treatment groups. At week 2 the 
RO32-3555 treated group showed increased lung consolidation relative to the 
vehicle and INH treated group (p<0.05 and p<0.001 respectively) (Figure 4-6).  
 
Between week 1 and week 2, the volume of the main lesion had increased in the 
RO32-3555 group in contrast to the INH and vehicle only groups in which the 
volume had decreased (Figure 4-7A). In a related measurement, it was also 
observed that the total lung volume decreased in the RO32-3555 treated animals 
in contrast to an increase in total lung volume in the INH and vehicle treated 
groups (Figure 4-7B). Most likely the increase in lung volume can be attributed 
to a decrease in lung consolidation and a relative increase in “healthy” lung 
tissue. A breath hold CT protocol is used in which the animals lungs are inflated 
to a set pressure. Normal lung tissue is able to inflate and expand under the 
increase in air pressure, but the consolidated lung tissue is not as pliable and 
allows for relatively little expansion. It would therefore follow that an increase in 
the volume of the main lesion would lead to a relative decrease in the total lung 
volume of the inflated lung.   
 
Cavities, unlike the first infection group, were observed in all treatment groups by 
CT imaging. The number of cavities and the size of cavities were lowest in the 
RO32-3555 treatment group as compared to the other treatment groups (Table 
4-1). Histopathology showed the presence of a cavitary lesion in 1 additional 





Two groups of animals were infected and treated orally with RO32-3555, INH, or 
vehicle alone as a control. In the first group of infections, rabbits were infected 
using a titrated frozen stock of bacteria. Bacteria were thawed, and directly used 
for animal infections. The rabbits appeared to be clearing the infection, and all 
treatment groups showed a decrease in lung consolidation over time and each 
treatment group returned to near baseline levels of lung consolidation by the end 
of the study. This can most likely be attributed to a decrease in fitness from the 
freeze-thawed cells and 104 CFU of the titrated frozen stock may not show 
equivalent growth in an animal host as 104 CFU from a freshly growing broth 
culture. Infections were done in this manner as an attempt to decrease the 
amount of variation across rabbit studies. However, this seemed to provide the 
unintended consequence that the newly thawed cells were not as fit and or 
virulent as broth cultured bacteria. At necropsy, the gross pathology displayed 
little signs of disease.  
 
The drug was able to provide an apparent benefit in the short term, however no 
benefit was observed at week 3 and beyond relative to the vehicle control. 
However since none of the rabbits cavitated in group 1, an assessment of the 
drugs effect on preventing cavitation could not be determined.  
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In the second study the rabbits did develop cavitary lesions. Lesions had 
developed in all groups but the volume and number of cavities were lower in the 
RO32-3555 treated animals. Treatment of rabbits with the RO32-3555 inhibitor 
alone was not sufficient to prevent cavitation, however use of the drug as part of 
antibiotic containing drug regimen may prove useful.  
 
The breakdown of the extracellular matrix requires the activity of special 
enzymes of the matrix metalloproteinase class. Cellular necrosis is not sufficient 
to break down the extracellular matrix. Cavitary lesion development has been 
classically described as the result of a granuloma that undergoes central 
necrosis. While we do not refute that necrosis is a necessary event that does 
occur during cavitary lesion development, we believe that the enzymatic 
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Figure 4-1: Group 1 study outline 
Rabbits were presensitized prior to infection. Rabbits underwent a series of 5 
subcutaneous sensitization injections of 108 heat killed bacilli in Freund's 
incomplete adjuvant. Following infection rabbits were treated daily with INH, 
RO32-3555, or vehicle alone. Rabbits underwent weekly set pressure CT scans 
and were necropsied at the end of the study.  
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Figure 4-2: Group 1 CT density plots 
Rabbits underwent weekly CT breath hold scans at 20 cm water pressure. Total 
lung regions were first segmented and then a global threshold of -200:200 HU 
was applied to define the pathological region of interest. This threshold selects 
dense tissue which is associated with disease. A) Preinfection scan shows no 
difference between groups. B) INH treated rabbits show less lung consolidation 
as compared to the vehicle group (p<0.01). C) Both the INH and RO32-3555 
treated groups show significantly less lung consolidation as compared to the 
vehicle control group (p<0.001). D) INH shows significantly less lung 
consolidation as compared to vehicle and RO32-3555 groups. E) RO32-3555 
animals show the greatest amount of lung consolidation (p<0.001). F) INH 
treated animals show the lowest amount of lung consolidation and RO32-3555 





Figure 4-3: Vasculitis 
The presence of vasculitis was observed in the RO32-3555 treatment group. 
Vasculitis had not been previously reported as a side effect of the drug. Further 
studies are needed to determine the effect of RO32-3555 on vasculitis in animals 






Figure 4-4: Group 2 study outline 
Rabbits were presensitized prior to infection. Rabbits underwent a series of 5 
subcutaneous sensitization injections of 108 heat killed bacilli in Freund's 
incomplete adjuvant. Following infection rabbits were treated daily with INH, 
RO32-3555, or vehicle alone. Rabbits underwent weekly set pressure CT scans 
and were necropsied at the end of the study. Rabbits were only monitored for 2 




Figure 4-5: Group 2, 3D lung images 
Rabbits underwent weekly set pressure CT scans. The lungs were inflated to a 
set pressure of 20 cm water to reduce the amount of breathing artifact. Animals 
were infected by bronchoscopy and the bacterial suspension was localized to 
single lung lobe. Cavities are indicated with red arrows. Cavities and signs of 















Figure 4-6: Group 2 CT density plots 
Rabbits underwent weekly CT breath hold scans at 20 cm water pressure. Total 
lung regions were first segmented and then a global threshold of -200:200 HU 
was applied to define the pathological region of interest. This threshold selects 
dense tissue which is associated with disease. A) Preinfection scan shows no 
difference between groups. B) No significant difference was observed between 
any treatment group at day 7 postinfection. C) The RO32-3555 treatment group 
showed the greatest amount of lung consolidation as compared to the vehicle 







Figure 4-7: Group 2 lung and lesion volume 
Changes in the volume of the main lesion (as defined by -200:200 HU threshold) 
and the total lung were measured. Healthy lung tissue should expand when 
inflated at 20 cm water, however the consolidated tissue has a decreased ability 
to expand. There was an inverse relationship between the change in volume of 
the A) main lesion and B) total lung.  
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Table 4-1: Cavity stats 
The number of cavities and cavity volume were measured by CT. The size and 
frequency of cavities was less in the RO32-3555 treatment group.  
 Vehicle (mm3) INH (mm3) RO32-3555 (mm3) 
Rabbit 1 381 (2 coalescing) 225; 75; 25 9 
Rabbit 2 caseum 35 0 
Rabbit 3 caseum 0 0 
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Image data sets from different modalities, PET and CT, were acquired on 
separate instruments with different spatial resolutions. PET image data sets were 
reconstructed at a resolution at 1 x 1 x 1 mm voxels; CT image data sets are 
reconstructed at 0.3 x 0.3 x 0.625 mm voxels. The data sets therefore have 
different spatial resolutions and additionally have different spatial coordinates. 
Differences in voxel size across data sets and also differences in spatial 
coordinates need to be resolved for successful image analysis. Following image 
coregistration, segmentation of the lungs and the associated disease pathology 
is a semi-automated process that requires user input and guidance of the image 




A general list of reference terms relating to image processing are summarized in 
Table 1-1. Images must be carefully coregistered and segmented for accurate 
image analysis. Data from [18F]-FDG PET scans provide functional data in which 
high uptake of the tracer results in a positive signal. In the context of infectious 
disease, the positive signal is likely attributed to the accumulation of the host 
immune cells at the site of an infection. Similarly, in the context of cancer, a 
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positive signal is likely due to the accumulation of cancer cells. PET images 
provide good functional data but lack adequate anatomical information. Therefore 
it is almost always necessary to coregister a PET data set with an image data set 
which provides good anatomical information such as CT or MRI. Two methods 
are described for coregistration and segmentation. The first method uses freely 
available software tools and the second method uses the commercially available 
Amira Imaging software tool (Visualization Sciences Group).  
 
Method 1- Annotation tool (NIH) 
 
Use of the annotation tool requires preprocessing of the input PET and CT 
images. Preprocessing is required for coregistration and also to make the voxel 
size uniform between PET and CT image sets (Figure 5-1, 5-2). These 
preprocessing steps are not required for use of Method 2 which makes use of the 
commercially available Amira Imaging software.  
 
1. Load PET and CT data into AMIDE [1]. 
2. Coregistration  
2.1. Point sources were fastened to the animal to aid in image 
coregistration. 2-5 µCi of PET tracer was added to PCR tubes for 
use as point sources. The PCR tubes can be identified by CT and 
the radioactive tracer can be identified by PET (Figure 5-3).  
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2.2. Coregistration was done using the using the “Alignment Wizard” 
under “Tools” → “Alignment Wizard” → “Fiduciary Markers”. The 
CT data stays fixed as the reference data set and the PET data is 
transformed for the coregistration process. 
2.3. Coregistered data sets are exported by “File” → “Export Data Sets” 
→ “Resliced Orientation” → “Analyze SPM” → “Bounding Box 
Inclusive of all data sets”. 
2.4. Data sets are coregistered but still contain voxel sizes of different 
dimensions.  
3. Normalization of voxel size using FIJI (Figure 5-4) [2]. 
3.1. Coregistered PET and CT data is first loaded into FIJI image 
processing software.  
3.2. If “a” = CT and “b”= PET, then the following operations are 
performed by “Process” → “Math” → “add...” (or subtract as 
needed): 
3.2.1. a +  b =  c 
3.2.2. c − a = b′; where b′is the PET data but now has equivalent 
voxel dimensions as the CT image set.  
4. Segmentation  
4.1. The Annotation Tool (NIH) allows for semi-automated segmentation 
of images and was developed by the Mollura lab at the NIH. This 
tool is planned to be freely distributed, but at the time of writing the 
tool was still under development for general release. 
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4.2.  Segmentation can be performed by a combination of tools 
available through the software platform such as thresholding or 
assisted region growing.  
4.2.1. Thresholding is done by selecting a density range and all 
voxels that fall between these defined regions are selected 
(Figure 5-5).  
4.2.2. Assisted region walking consists of 2 labeling steps. First, 
seed points are selected in which the user selects 
representative regions that should be included in the region 
of interest. Next the user selects several seed points that are 
representative of regions that should not be included in the 
region of interest (Figure 5-6).  
4.3. After successful segmentation of the lung, the binary mask is 
exported. The binary mask can then be loaded into FIJI along with 
the coregistered PET and CT data sets. 
4.4. The final step of segmentation is completed by multiplying the 
binary mask and the PET or CT data set of interest by “Process” → 
“Math” → “multiply...” (Figure 5-7).  
5. Histogram plots 
5.1. Load lung masks into FIJI 




Method 2: Amira Visualization Sciences Group 
 
Use of the Amira software package does not require the use of any additional 
software for image processing. No additional steps are needed for normalization 
of voxel sizes between different image data sets. Amira is also capable of image 
coregistration and segmentation.  
 
1. Load PET and CT data into AMIRA. 
2. Coregistration 
2.1. PET and CT files are manually coregistered in the “multi planer 
viewer”. Point sources are identified in the PET and CT viewers. 
Unlike in AMIDE, the point sources are not labeled with fiducial 
markers (Figure 5-8, 5-9). 
2.2. Selection of the “transform editor options” and “manual registration 
tool” allows for manipulation of the “overlay data set” in relation to 
the primary data set (Figure 5-10, 5-11).  
3. Segmentation 
3.1. Segmentation is performed using the “Segmentation editor”. Amira 
organizes the segmentation process into 2 levels. The first level is 
known as the “label” class. Multiple segmentations can be made 
and saved under a “label” and these are known as “materials”. For 
example a “label” can be named LUNG and examples of possible 
“materials” are lung, airway, and esophagus. It is important to note 
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that voxels can only belong to a single “material” and a voxel 
cannot be included under multiple “materials”. It is necessary to first 
duplicate the original label that contains the segmented lung befor 
further segmentation of the lung is carried out. This can be 
accomplished from the “Tree view viewer” and using the right 
mouse click to “duplicate object”. Further lung segmentation should 
be done using the duplicated object.   
3.2. The first step is to segment the entire lung; including both 
pathologic and non-pathologic tissue. A new label named Lung 
should be created. Segmentation should be performed using the 
CT data set (Figure 5-12). 
3.2.1. The “lasso”, “brush”, “magic wand”, and “threshold” tools can 
all be used as needed. Generally a combination of all tools 
will be required for proper segmentation.    
3.3. Duplicate the Lung label and use the copy for further lung 
segmentation.  
3.3.1. Pathologic lung segmentation can be done using a defined 
threshold scale. Consolidation was defined as -200:200 HU 
(Figure 5-13).  
3.3.2. The Lung label that was created using the CT as a template 
can then applied to the PET data set (Figure 5-14). 
Pathologic segmentation of the PET data set was done 
using a threshold of the top 5% percentile of PET uptake.   
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4. Histogram Plots 
4.1.  From the “Tree view viewer”, select the “label” of interest and 
select “measure” → “histogram” (Figure 5-15). 
4.2. From the “histogram” window, select the appropriate “data” (PET or 
CT), the “label” to be applied, and lastly the specific “material” to be 
analyzed. Output files should be saved as “.csv” for later use 
(Figure 5-16).  
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Figure 5-1: Image coregistration 
Image preprocessing may be required for proper coregistration of images with 
different spatial size and spatial location. The wire bounding boxes represent the 
relative spatial size and location of the initial CT (black rectangle) and the PET 
(blue rectangle). A) The starting position of each respective data set prior to 
coregistration and normalization of voxel size. B) Transformation and 
coregistration of PET and CT data sets. C) Transformation and coregistration of 




Figure 5-2: Voxel size 
PET image data sets are reconstructed at a resolution of 1 x 1 x 1 mm voxel size. 
CT image data sets are reconstructed at a resolution of 0.3 x 0.3 x 0.625 mm 
voxel size. For proper coregistration of data sets to be used with the Method 1 
data processing, preprocessing of the data sets is required to normalize voxel 





Figure 5-3: Point source coregistration 
Point sources are used to for accurate coregistration of PET and CT image sets. 
PCR tubes filled with 2-5 µCi of [18F]-FDG tracer were used as point sources. 
The PCR tube is identified and labeled with a fiducial mark using the AMIDE 
image processing software. The PET active tracer was labeled with a fiducial 
mark in the PET data set. Successful coregistration can be observed in the 
merged image. The liver shows high uptake of tracer as expected.    
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Figure 5-4: Voxel normalization 
The PET data set is composed of larger voxels relative to the CT data set. It is 
necessary for some analysis platforms that both data sets are composed of the 
same sized voxels. Voxel size can be normalized using the math functions 
included in FIJI. “Process” → “Math” → “Add…” (or “Subtract…” as needed). a) 
coregistered PET. b) coregistered CT. c) sum of 𝑎 + 𝑏. d) difference of 𝑐 − 𝑏. The 
basic process can be summarized by the following equations: 1) 𝑎 + 𝑏 = 𝑐; 2) 





Figure 5-5: Annotation tool threshold 
Segmentation can be performed by thresholding. In this method, a density range 
is defined and all values within that range are selected. However as can be seen 
by the binary mask and overlay, not all parts of the lung are included. In general, 
thresholding will allow for the capture of pathologically uninvolved tissue, but will 
not allow for the inclusion of pathologically involved tissue. The density of 
pathologically involved lung tissue is similar to the density of surrounding muscle, 
fat, liver, or heart tissue. Selecting a threshold that will include pathologically 






Figure 5-6: Annotation tool region walking 
One of the more powerful options available is the trainable region walking 
method. In this segmentation method, the user selects seed points that represent 
regions to be included as denoted by the blue dots. The user then selects 
regions that are not to be included as represented by the red dots. The computer 
generated region of interest consists of the area bounded by the green and red 
boundaries. This segmentation method was successful in specifically capturing 





Figure 5-7: Annotation Tool final 
A summary of the coregistration and segmentation process using Method 1. Raw 
data is loaded in AMIDE as represented in a and b. The coregistered images are 
shown in c. The resulting image data sets are then processed in FIJI to normalize 
voxel size across different imaging sets. The binary mask in d is generated with 
the Annotation Tool. Final segmented lungs are the result of applying the binary 





Figure 5-8: Amira CT point source 
PCR tubes filled 3 µCi of [18F]-FDG tracer were used as point sources for 
coregistration of CT and PET images. Point sources can be identified in the CT 
view by adjusting the window to -1000:-200 HU. This window is not optimal for 





Figure 5-9: Amira PET point source 
PCR tubes filled 3 µCi of [18F]-FDG tracer were used as point sources for 
coregistration of CT and PET images. CT data is loaded into the “Primary Data” 
panel and PET data is loaded into the “Overlay Data” panel. Point sources can 
be identified in the PET view by adjusting the window to maximize the signal from 





Figure 5-10: Amira coregistration 
Manual coregistration can be done from the “Multi planer viewer”. Selection of 
the “Registration tool” from the top tool bar and the “Transform editor options” 
from the lower left corner allow for manual manipulation of the “overlay data” 
image set. The image set can be transformed in all 3 planes by manipulation of 





Figure 5-11: Amira coregistration overlay 
Successful coregistration is visually confirmed by point source localization 
between both data sets. The signal from the point sources should be localized to 





Figure 5-12: Amira CT segmentation 
Segmentation is performed using the “Segmentation Editor”. CT data is loaded 
as the image data set and a new “label” is created. Next a new material lung is 
created. Segmentation can be accomplished using a combination of the “brush”, 
“lasso”, “magic wand”, and “threshold” tools. It will most likely be necessary to 





Figure 5-13: Amira pathologic lung segmentation 
Segmentation of pathologically involved lung tissue is done following the 
segmentation of the entire lung. Because individual voxels can only be attributed 
to a single material, it will be necessary to first duplicate the “label” containing the 
original lung segmentation. Segmentation of the pathologically involved tissue 
will be carried out using the copy of the original “label”. Defined threshold ranges 
are used to segment pathologically involved regions of interest. Threshold 





Figure 5-14: Amira PET segmentation 
The “Label Data” generated from the CT data can be applied to the PET data as 
well by simply selecting the appropriate “Image Data” and “Label Data” from the 
dropdown menus. After defining the lung window in the PET data set, it is then 





Figure 5-15: Amira histogram 
Selection of the label data for histogram analysis can be done through the “Tree 




Figure 5-16: Amira histogram file 
Selection of the “histogram” module from the “Tree view viewer” brings up the 
options panel that is represented in the lower left quadrant. The appropriate 
variables that need to be supplied are “data set”, “label”, “range”, “number of 
bins”, and “materials”. After the histogram plot is created, the raw data can be 
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